FZD4 — frizzled class receptor 4

The FZD4 gene provides instructions for making a protein called Frizzled-4, which sits on the surface of cells and acts like an antenna. This antenna is specifically designed to receive signals that are crucial for the normal development of blood vessels in the eye, particularly in the retina (the light-sensitive tissue at the back of the eye). When the Frizzled-4 protein receives these signals, it tells the cells to grow and form a healthy network of blood vessels that supply oxygen and nutrients to the retina. When there is a mutation (a harmful change) in the FZD4 gene, the Frizzled-4 "antenna" doesn't work correctly. As a result, the blood vessels in the retina do not develop fully or properly, leaving the outer edges of the retina without a sufficient blood supply. This condition is known as Familial Exudative Vitreoretinopathy (FEVR). To compensate for the lack of oxygen, the eye may try to grow new, fragile blood vessels, which can leak fluid or bleed, leading to scarring and potentially causing the retina to detach, which can result in vision loss. FZD4-related FEVR is most commonly inherited in an autosomal dominant pattern, meaning that a person only needs one mutated copy of the gene (inherited from either parent) to have the condition. However, the severity of the disease can vary greatly even within the same family. Some people with the mutation may have no noticeable vision problems, while others may experience severe vision loss in childhood. Because of this variability, genetic testing and careful eye exams are important for families with a history of FEVR to ensure early detection and treatment.

Gene description: FZD4 encodes a Wnt receptor involved in retinal vascular development and angiogenesis.

Patient and family guide: The FZD4 gene provides instructions for making a protein called Frizzled-4, which sits on the surface of cells and acts like an antenna. This antenna is specifically designed to receive signals that are crucial for the normal development of blood vessels in the eye, particularly in the retina (the light-sensitive tissue at the back of the eye). When the Frizzled-4 protein receives these signals, it tells the cells to grow and form a healthy network of blood vessels that supply oxygen and nutrients to the retina. When there is a mutation (a harmful change) in the FZD4 gene, the Frizzled-4 "antenna" doesn't work correctly. As a result, the blood vessels in the retina do not develop fully or properly, leaving the outer edges of the retina without a sufficient blood supply. This condition is known as Familial Exudative Vitreoretinopathy (FEVR). To compensate for the lack of oxygen, the eye may try to grow new, fragile blood vessels, which can leak fluid or bleed, leading to scarring and potentially causing the retina to detach, which can result in vision loss. FZD4-related FEVR is most commonly inherited in an autosomal dominant pattern, meaning that a person only needs one mutated copy of the gene (inherited from either parent) to have the condition. However, the severity of the disease can vary greatly even within the same family. Some people with the mutation may have no noticeable vision problems, while others may experience severe vision loss in childhood. Because of this variability, genetic testing and careful eye exams are important for families with a history of FEVR to ensure early detection and treatment.

Gene function: FZD4 is a crucial component of the Wnt signaling pathway, specifically mediating signals important for the proper development of the retinal vasculature. It plays a vital role in angiogenesis and maintaining the integrity of blood vessels in the retina. Mutations lead to abnormal retinal vascularization, causing conditions like familial exudative vitreoretinopathy, which impairs retinal function.

Protein structure: The FZD4 gene encodes the Frizzled-4 protein, which is a member of the G protein-coupled receptor (GPCR) superfamily. The human Frizzled-4 protein consists of 537 amino acids and features a classic seven-pass transmembrane structure. It contains a signal peptide at the N-terminus, followed by a large extracellular domain, seven hydrophobic transmembrane alpha-helices, and an intracellular C-terminal tail. The most critical functional region of the Frizzled-4 protein is the extracellular cysteine-rich domain (CRD), which is responsible for binding its specific ligands, particularly Norrin and Wnt proteins. The intracellular loops and the C-terminal tail are essential for interacting with downstream signaling molecules, such as Dishevelled (DVL). Frizzled-4 functions as part of a larger multi-protein receptor complex at the cell membrane, assembling with the co-receptor LRP5 and the tetraspanin protein TSPAN12 to effectively capture Norrin and initiate intracellular signaling cascades.

Molecular function: The FZD4 gene encodes Frizzled-4, a seven-transmembrane domain protein that functions as a receptor in the Wnt signaling pathway. Uniquely among the Frizzled family, FZD4 acts as the specific receptor for Norrin (encoded by the NDP gene), a secreted protein that is structurally unrelated to Wnt ligands but activates the canonical Wnt/beta-catenin signaling pathway. In the retina, Norrin is secreted by Müller glia and binds to the FZD4 receptor complex on the surface of vascular endothelial cells. The functional receptor complex requires the presence of the co-receptor LRP5 and the auxiliary membrane protein TSPAN12. Upon binding of Norrin to FZD4 and LRP5, the signal is transduced intracellularly via Dishevelled (DVL) proteins, leading to the stabilization and nuclear translocation of beta-catenin. This canonical signaling cascade activates the transcription of target genes essential for the proliferation, migration, and maturation of endothelial cells, thereby driving normal retinal angiogenesis and the establishment of the blood-retina barrier (BRB). Loss of FZD4 function disrupts this critical signaling, resulting in the hypovascularity characteristic of FEVR.

Expression pattern: The FZD4 gene is widely expressed across various tissues, but it has particularly high and critical expression in the retina, specifically within the endothelial cells of the developing and mature retinal vasculature. It is also expressed in the inner ear, brain, kidney, liver, and ovary. In the central nervous system, FZD4 is found on the surface of endothelial cells where it plays a vital role in the formation and maintenance of the blood-brain and blood-retina barriers. During development, FZD4 expression is temporally regulated to coincide with the period of active angiogenesis in the retina. Single-cell transcriptomic studies have also identified FZD4 expression in various retinal cell types, including amacrine cells, horizontal cells, and retinal ganglion cells, although its primary functional significance is most strongly linked to the vascular endothelium.

Mutation spectrum: The mutation spectrum of the FZD4 gene in FEVR is diverse, encompassing missense, nonsense, frameshift, and splice-site mutations, as well as large genomic deletions. Missense mutations are the most frequently reported type and are distributed throughout the gene, though many cluster within the extracellular cysteine-rich domain (CRD), which is critical for ligand binding, or within the transmembrane domains essential for structural integrity and signal transduction. There are no universally dominant hotspot regions, but the CRD is a notable region of mutational density. The total number of known pathogenic variants in FZD4 is continually expanding, with dozens of distinct mutations identified in FEVR cohorts worldwide. Most FZD4 mutations are inherited in an autosomal dominant manner, leading to haploinsufficiency or dominant-negative effects, though rare autosomal recessive cases involving biallelic mutations have also been documented.

Pathogenic variants: 1. p.Met105Val - A well-characterized missense mutation located in the extracellular cysteine-rich domain (CRD), known to impair Norrin binding and subsequent Wnt/beta-catenin signaling, leading to autosomal dominant FEVR. 2. p.Arg417Gln - A missense mutation affecting the transmembrane region, which disrupts the structural conformation and membrane localization of the receptor, resulting in defective signaling and FEVR. 3. p.Gly488Asp - Another significant missense variant that interferes with the receptor's ability to properly transduce the Norrin signal, associated with variable severity of FEVR. 4. c.1501_1502del - A frameshift mutation (deletion) that leads to a premature stop codon and a truncated, non-functional protein, causing a severe loss of function and presenting as FEVR. 5. p.Tyr250Cys - A recently identified missense variant that influences the Norrin/beta-catenin signaling pathway, expanding the known mutational spectrum associated with FEVR pathogenesis.

Clinical significance: Mutations in the FZD4 gene are a major cause of Familial Exudative Vitreoretinopathy (FEVR), specifically designated as EVR1. FEVR is characterized by the incomplete or aberrant development of the retinal vasculature, particularly in the peripheral retina. The clinical manifestations are highly variable, even among family members carrying the same mutation. Mild cases may be asymptomatic and only detectable through wide-field fluorescein angiography, which reveals an avascular peripheral retina. More severe cases can present in infancy or early childhood with significant visual impairment. These patients may develop retinal folds, temporal dragging of the macula, retinal exudates, neovascularization, and tractional retinal detachment, which can lead to blindness if left untreated. While FEVR is primarily an ocular condition, some severe cases with biallelic FZD4 mutations have been associated with systemic features such as congenital hearing loss and developmental delay, highlighting the gene's broader role in neurovascular development.

Inheritance: Autosomal Dominant

Chromosomal location: 11q14.2

Genotype-phenotype correlations: Genotype-phenotype correlations in FZD4-related FEVR are notably complex and characterized by significant phenotypic heterogeneity. Patients with FZD4 mutations generally exhibit a broad spectrum of disease severity, ranging from asymptomatic peripheral avascularity to severe, early-onset retinal detachment. Some studies suggest that mutations resulting in a complete loss of function (such as large deletions, nonsense, or frameshift mutations) may correlate with more severe phenotypes compared to certain missense mutations, though this is not an absolute rule. Interestingly, patients with FZD4 mutations often display a relatively milder but broader spectrum of phenotypes compared to those with NDP mutations, and they frequently show asymmetry in disease severity between the two eyes. Biallelic FZD4 mutations (homozygous or compound heterozygous) are rare but are typically associated with a much more severe clinical course, often presenting in infancy with profound visual loss and sometimes accompanied by systemic issues like hearing loss.

Research and therapeutic approaches: Currently, there are no FDA-approved gene therapies or targeted pharmacological treatments specifically for FZD4-related FEVR. The standard of care relies on surgical and laser interventions to manage the complications of the disease. These include laser photocoagulation or cryotherapy applied to the avascular peripheral retina to prevent neovascularization and exudation, and vitrectomy surgery to repair retinal detachments in advanced stages. Anti-VEGF (vascular endothelial growth factor) injections are also sometimes used off-label to manage active neovascularization and reduce exudation. In the research pipeline, therapeutic strategies are focusing on restoring or bypassing the defective Norrin/Wnt signaling pathway. Investigational approaches include the development of Frizzled4-LRP5 agonists or Norrin mimetics designed to activate the canonical Wnt pathway and promote normal blood-retina barrier function and angiogenesis. These small molecules or engineered proteins have shown promise in preclinical animal models (such as Fzd4 knockout mice) by inducing de novo barrier formation and reducing vascular leakage. While gene therapy (like Luxturna for RPE65) is not yet available for FZD4, the advancement of viral vector delivery systems to the retina holds potential for future gene replacement strategies for patients with loss-of-function mutations.

Diagnostic testing: Diagnostic testing for FZD4 mutations typically involves targeted gene panel testing for FEVR and related inherited retinal diseases, which includes FZD4 along with other key genes in the Norrin/Wnt signaling pathway (such as LRP5, NDP, and TSPAN12). Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be employed, particularly when panel testing is negative or when the clinical presentation is complex. Wide-field fluorescein angiography is a crucial clinical diagnostic tool that often prompts genetic testing by revealing the characteristic peripheral avascularity. Genetic counseling is essential for families affected by FZD4 mutations. Since FZD4-related FEVR most commonly follows an autosomal dominant inheritance pattern with incomplete penetrance and highly variable expressivity, asymptomatic family members may carry the mutation and be at risk of passing it to their offspring. Identifying the specific mutation helps confirm the diagnosis, guides the screening of at-risk relatives, and informs family planning decisions.

Animal models: Fzd4 knockout (Fzd4-/-) mice are the primary animal models used to study FEVR and the role of FZD4 in retinal vascularization. These mice exhibit severe defects in the development of the intraretinal vasculature, closely mimicking the hypovascular phenotype seen in human FEVR patients. They also display abnormalities in the inner ear vasculature, leading to progressive hearing loss, which mirrors the systemic manifestations occasionally observed in severe human cases. Additionally, these models have been instrumental in demonstrating that FZD4 is essential for the blood-retina barrier (BRB) integrity, as the knockout mice show increased vascular permeability and retinal exudation. Heterozygous Fzd4+/- mice generally do not show the severe retinal vascular abnormalities seen in homozygous knockouts, suggesting that haploinsufficiency in mice may not fully replicate the autosomal dominant inheritance pattern often seen in human FEVR. However, conditional knockout models and specific point mutation knock-in mice have been developed to better understand the precise temporal and spatial requirements of FZD4 signaling during retinal angiogenesis and to test potential therapeutic interventions, such as Wnt/Norrin pathway agonists.

Population genetics: FZD4 mutations are a leading genetic cause of Familial Exudative Vitreoretinopathy (FEVR), accounting for a significant proportion of cases worldwide. The exact carrier frequency in the general population is not well-established due to the rarity of the condition and the high degree of incomplete penetrance and variable expressivity, which means many carriers may remain undiagnosed if they are asymptomatic. Studies in various populations, including large cohorts in China and Western countries, have consistently identified FZD4 as one of the top two or three most frequently mutated genes in FEVR patients, alongside LRP5 and NDP. There are no widely recognized founder mutations for FZD4, as pathogenic variants are generally diverse and distributed across different ethnic groups.

Selected references: 1. Robitaille J, et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet, 2002. PMID: 12172548 2. Kondo H, et al. Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. Br J Ophthalmol, 2003. PMID: 14609843 3. Qin M, et al. Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum Mutat, 2005. PMID: 15981244 4. Junge HJ, et al. TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell, 2009. PMID: 19837033 5. Wang X, et al. A systematic review and meta-analysis on more than 3200 patients with familial exudative vitreoretinopathy. PLoS One, 2022. PMID: 35857764 6. Drenser KA, et al. Clinical presentation and genetic correlation of patients with mutations in FZD4. JAMA Ophthalmol, 2009. PMID: 19901214 7. Qian Y, et al. Structural basis of Frizzled 4 in recognition of Dishevelled 2 and its implication in FEVR. Nat Commun, 2024. PMID: 39294154